David Aboulafia, MD
Hematology & Oncology · Seattle, WANPI 1043269392
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,041 of the $22,455 with a category attached, or 80.3%. It is spread thinly across 13 manufacturers, the largest accounting for just 18.1%. Reporting peaked in 2019 at $8,377 and has fallen 71.2% since, to $2,412 in 2025.
Across 29 payments — averaging $774.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- AstraZeneca$3K
- Sanofi$3K
- E.r. Squibb & Sons, L.L.C.$3K
- AbbVie$3K
- Pfizer$2K
- plus $4K from 7 others
Across 108 payments — averaging $3509.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$150K
- Incyte Corporation$85K
- Seagen Inc.$52K
- Takeda Pharmaceuticals U.S.A., Inc.$33K
- Orphai Therapeutics Inc.$30K
- Bristol Myers Squibb$19K
- plus $10K from 2 others
What the payments were for
- Consulting fees$18,04180%
- Speaking & faculty fees$3,00013%
- Travel & lodging$4252%
- Food & beverage$6643%
- Education$3251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 8 | $4,058 |
| AstraZeneca | 2 | $3,444 |
| Sanofi | 2 | $3,071 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,882 |
| AbbVie | 3 | $2,835 |
| Pfizer | 1 | $2,250 |
| Genmab U.S., Inc. | 3 | $2,228 |
| Theratechnologies Inc. | 3 | $875 |
| Beigene, Ltd. | 1 | $525 |
| Janssen Products, LP | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Epizyme, Inc. | 1 | $80 |
| Beigene USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,455 in reported general payments places this provider in the 80th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JulucaDolutegravir/Rilpivirine | 223 | $815,964 |
| PomalystPomalidomide | 37 | $798,125 |
| RevlimidLenalidomide | 44 | $745,498 |
| OjjaaraMomelotinib Dihydrochloride | 26 | $722,103 |
| Lenalidomide | 55 | $708,067 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 150 | $619,331 |
| BrukinsaZanubrutinib | 40 | $586,485 |
| NinlaroIxazomib Citrate | 36 | $460,850 |
| JakafiRuxolitinib Phosphate | 24 | $424,610 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 88 | $412,583 |
| PromactaEltrombopag Olamine | 29 | $288,561 |
| DescovyEmtricitabine/Tenofov Alafenam | 132 | $284,784 |
| ScemblixAsciminib Hydrochloride | 12 | $260,260 |
| CalquenceAcalabrutinib Maleate | 16 | $243,404 |
| EvotazAtazanavir Sulfate/Cobicistat | 124 | $221,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Evotaz | $2,882 | $1,020,040161 claims |
| GileadBiktarvy, Descovy, Genvoya | $4,058 | $913,763273 claims |
| Beigene USA, Inc.Brukinsa | $8 | $586,48540 claims |
| AstraZenecaCalquence | $3,444 | $243,40416 claims |
| PfizerEliquis | $2,250 | $98,66392 claims |
| Janssen Products, LPSymtuza | $100 | $51,76211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.